QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of dasatinib and abarelix. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for dasatinib, when combined with abarelix (100%). We do not expect any change in exposure for abarelix, when combined with dasatinib (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of dasatinib is unknown. The terminal half-life [ t12 ] is rather short at 3.15 hours and constant plasma levels [ Css ] are reached quickly. The protein binding [ Pb ] is 96% strong and the volume of distribution [ Vd ] is very large at 175350 liters. The metabolism mainly takes place via CYP3A4 and the active transport takes place in particular via PGP.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither dasatinib nor abarelix increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither dasatinib nor abarelix increase anticholinergic activity.
QT time prolongation
Rating: In combination, dasatinib and abarelix can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||das||aba|
|Musculoskeletal pain||45.5 %||45.5||n.a.|
|Abdominal pain||44.5 %||44.5||n.a.|
Rash (41%): dasatinib
Hypersensitivity reaction (36%): dasatinib
Infection (9.5%): dasatinib
Peripheral edema (34.5%): dasatinib
Fatigue (34%): dasatinib
Pleural effusion (24%): dasatinib
Dyspnea (19%): dasatinib
Pneumonia (14.5%): dasatinib
Pulmonary hypertension (3.5%): dasatinib
Pulmonary edema (2.5%): dasatinib
Hemorrhage (17%): dasatinib
Gastrointestinal hemorrhage (5.5%): dasatinib
Pericardial effusion (3.5%): dasatinib
Intracranial hemorrhage (3%): dasatinib
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.